Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...

Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

Scientists say they have found a pattern of so-called epigenetic 'marks' in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may keep at least a ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein ...

KRAS mutations, especially G12D, G12V, and G12C, are highly prevalent in pancreatic, colorectal, and lung cancers. First-generation KRAS inhibitors have demonstrated clinical benefit, but their ...

ALTA3263 is an oral KRAS-selective inhibitor specifically designed ... cancer (NSCLC), pancreatic ductal carcinoma (PDAC), and colorectal cancer (CRC). “With this trial, we hope to bring a ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...